期刊
MUSCLE & NERVE
卷 64, 期 2, 页码 153-155出版社
WILEY
DOI: 10.1002/mus.27261
关键词
gene replacement; preterm; SMA; spinal muscular atrophy; treatment
Newborn screening for SMA and increased genetic carrier screening in 33 US states have led to an increase in early, presymptomatic diagnosis of SMA. Early treatment is crucial for infants with SMA, especially for those who are presymptomatic.
Implementation of newborn screening for spinal muscular atrophy (SMA) in 33 US states and increased genetic carrier screening have led to an increase in early, presymptomatic diagnosis of SMA. Early treatment is critically important and is recommended for presymptomatic infants with two to four copies of survival motor neuron 2. Currently, no specific treatment recommendations exist for preterm infants with SMA. The US Food and Drug Administration does not recommend using onasemnogene abeparvovec-xioi in preterm infants. Some insurance companies interpret preterm to be less than 40 weeks gestational age (GA) instead of the commonly accepted 37 weeks GA, which can be a barrier to treatment access. Given the risk of rapid decline in some infants, we recommend treatment of preterm infants when they reach 37 weeks GA, based on the definitions of term GA from the World Health Organization and Centers for Disease Control and Prevention, assuming all other treatment criteria are met.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据